Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524A in primary hypercholesterolemia or mixed dyslipidemia
NCT01335997Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- May 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of Niacin + laropiprant + simvastatin in hypercholesterolemia, mixed dyslipidemia, sponsored by Merck & Co.. Started May 2011; status: terminated.
02
Drugs
Niacin + laropiprant + simvastatin
03
Conditions
hypercholesterolemiamixed dyslipidemia
Beyond the preview
Go deeper on NCT01335997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01335997.